as 09-05-2025 3:21pm EST
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Founded: | 1996 | Country: | Canada |
Employees: | N/A | City: | BURNABY |
Market Cap: | 2.4B | IPO Year: | 2014 |
Target Price: | $52.73 | AVG Volume (30 days): | 834.3K |
Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -3.54 | EPS Growth: | N/A |
52 Week Low/High: | $26.74 - $46.00 | Next Earning Date: | 08-11-2025 |
Revenue: | $7,500,000 | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | 256.34% |
XENE Breaking Stock News: Dive into XENE Ticker-Specific Updates for Smart Investing
Simply Wall St.
12 days ago
Simply Wall St.
15 days ago
GlobeNewswire
2 months ago
MT Newswires
3 months ago
Zacks
3 months ago
GlobeNewswire
3 months ago
GlobeNewswire
3 months ago
GlobeNewswire
4 months ago
The information presented on this page, "XENE Xenon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.